SARC045: Tebentafusp in Advanced Clear Cell Sarcoma
Research type
Research Study
Full title
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients with Advanced Clear Cell Sarcoma
IRAS ID
1012905
Contact name
Meghan Blalock
Contact email
Sponsor organisation
SARC (Sarcoma Alliance for Research through Collaboration)
ISRCTN Number
ISRCTN24846895
Clinicaltrials.gov Identifier
Research summary
Clear cell sarcoma (CCS) is a rare type of soft tissue cancer which has very limited treatment options. In this research study patients with advanced CCS will be treated with tebentafusp, a drug which is approved for melanoma. Previous research showed that melanoma treatment could also work for patients with CCS. In this clinical trial the researchers will try to find out if the drug will work for patients with CCS and how long the effect will last for if it works. The researchers will also collect tissue and blood samples to learn about the effect of the drug and the mechanisms of action. The patients will have regular visits to clinic to have blood samples and other assessments including radiology assessments. Patients will be treated until disease progression, consent withdrawal or unacceptable toxicity. Patients who have clinical benefit can remain on the study after disease progression. At the end of the treatment the patients will have follow up every 3 months.
REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
25/EM/0257
Date of REC Opinion
28 Jan 2026
REC opinion
Further Information Favourable Opinion